Featured
-
-
Article
| Open Access
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3 bispecific antibodies (bsAbs) have demonstrated promising clinical responses in hematological malignancies but clinical benefit in solid tumors has been limited. Here the authors report that pre-treatment vaccination promotes the infiltration of tumor-(un)related effector CD8 T cells, improving the efficacy of CD3 bsAbs in solid tumors.
- Jim Middelburg
- , Marjolein Sluijter
- & Thorbald van Hall
-
Article
| Open Access
A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils
Vaccines that specifically induce immunity against bacterial pathogens are required. Here the authors produce and characterize an intranasal liposomal vaccine against a peptide antigen from Streptococcus pyogenes and show that it induces a strong mucosal IgA response lasting for over one year, and that protection is dependent on cellular immunity mediated through IL-17, macrophages and neutrophils.
- Victoria Ozberk
- , Mehfuz Zaman
- & Manisha Pandey
-
Article
| Open Access
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Here, Heitmann et al. report results from a Phase I/II trial evaluating CoVac-1, a peptide-based T-cell activator, in patients with B-cell deficiency, demonstrating potent induction of SARS-CoV-2-specific T-cell responses along with a favorable safety profile.
- Jonas S. Heitmann
- , Claudia Tandler
- & Juliane S. Walz
-
Article
| Open Access
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
Vaccination regimens and the number of doses required for optimal immunity and protection are critical factors in the translation of vaccines. Here the authors show administration of a three dose protocol of a single T cell epitope to the SARS-CoV-2 spike protein induces a robust CD8+ T cell response and confers protection in a lethal murine challenge model of infection.
- Iris N. Pardieck
- , Tetje C. van der Sluis
- & Ramon Arens
-
Article
| Open Access
Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells
The success of peptide vaccine treatment in cancer relies on the build-up of an efficient cytotoxic T cell response against the tumour antigen. Authors show here that tumour-specific memory CD8 T cells are able to persist and possibly even proliferate in the peripheral blood of long-surviving hepatocellular carcinoma patients.
- Eishiro Mizukoshi
- , Hidetoshi Nakagawa
- & Shuichi Kaneko
-
Article
| Open Access
Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine
In this phase 2 clinical trial, the authors assess protective efficacy of a Plasmodium vivax circumsporozoite vaccine in naïve and semi-immune individuals from controlled human malaria infection as well as antibody and IFN-γ response to vaccination.
- Myriam Arévalo-Herrera
- , Xiomara Gaitán
- & Sócrates Herrera
-
Article
| Open Access
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Successful cancer immune therapy correlates with a T cell-inflamed tumour microenvironment. Authors show here that co-administration of a self-adjuvanting protein vaccine and an antigen-expressing oncolytic virus in an optimised regimen strongly enhances T cell immunogenicity and may turn non-inflamed tumours proinflammatory and less resistant to checkpoint blockade therapy.
- Krishna Das
- , Elodie Belnoue
- & Guido Wollmann
-
Article
| Open Access
Repertoire-scale determination of class II MHC peptide binding via yeast display improves antigen prediction
Identifying peptides that can bind major histocompatibility complex II (MHC-II) is important for our understanding of T cell immunity and specificity. Here the authors present a yeast-display library screening approach that identifies more potential binders than various reported algorithms to help expand our understanding for antigen presentation.
- C. Garrett Rappazzo
- , Brooke D. Huisman
- & Michael E. Birnbaum
-
Article
| Open Access
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
Senotherapy, the removal of aged T cells, is an effective approach to attenuate age-related diseases. Here the authors report a CD153 targeting vaccine that prevents the accumulation of senescent adipose tissue T cells in mice on high-fat diet, which is associated with improved glucose tolerance.
- Shota Yoshida
- , Hironori Nakagami
- & Hiromi Rakugi
-
Article
| Open Access
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours
Tumours can escape CD8 T-cell immunity by down-regulating antigen presentation machinery components, such as TAP. Here the authors describe tumour antigenic peptides processed by TAP-independent and -dependent pathways and show in mouse models that these peptides can be exploited to induce antitumor T-cell activity when TAP expression is downregulated.
- Aurélie Durgeau
- , Yasemin Virk
- & Fathia Mami-Chouaib
-
Article
| Open Access
P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5
The secretedPlasmodium falciparum protein RH5 is essential for invasion of erythrocytes and is a promising vaccine candidate. Here, Galaway et al. show that the N-terminal region of RH5 binds the GPI-anchored merozoite surface protein P113 and can elicit invasion-blocking antibodies.
- Francis Galaway
- , Laura G. Drought
- & Gavin J. Wright
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial